Trademark: 79207192
Word
HUMABFC
Status Date
Tuesday, July 10, 2018
Registration Number
5510331
Registration Date
Tuesday, July 10, 2018
Filing Date
Wednesday, December 14, 2016
Published for Opposition
Tuesday, April 24, 2018
5 Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing
42 Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; scientific laboratory services in the field of monoclonal antibodies
May 13, 2017
Non-Final Action Written
May 11, 2017
Sn Assigned For Sect 66a Appl From Ib
May 13, 2017
New Application Office Supplied Data Entered
May 13, 2017
Assigned To Examiner
May 14, 2017
Non-Final Action (Ib Refusal) Prepared For Review
May 17, 2017
Application Filing Receipt Mailed
May 23, 2017
Refusal Processed By Mpu
May 23, 2017
Non-Final Action Mailed - Refusal Sent To Ib
Nov 14, 2017
Correspondence Received In Law Office
Jun 10, 2017
Refusal Processed By Ib
Oct 24, 2017
Teas Response To Office Action Received
Nov 3, 2017
Assigned To Lie
Nov 14, 2017
Teas/Email Correspondence Entered
Dec 11, 2017
Final Refusal Written
Dec 11, 2017
Final Refusal E-Mailed
Dec 11, 2017
Notification Of Final Refusal Emailed
Mar 5, 2018
Teas Request For Reconsideration Received
Mar 5, 2018
Correspondence Received In Law Office
Mar 6, 2018
Teas/Email Correspondence Entered
Apr 24, 2018
Official Gazette Publication Confirmation E-Mailed
Mar 17, 2018
Approved For Pub - Principal Register
Apr 4, 2018
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Apr 4, 2018
Notification Of Notice Of Publication E-Mailed
Apr 4, 2018
Notification Of Possible Opposition Sent To Ib
Apr 20, 2018
Notification Processed By Ib
Apr 24, 2018
Published For Opposition
Mar 5, 2021
New Representative At Ib Received
Apr 3, 2021
Correction Transaction Received From Ib
Jul 10, 2023
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Jul 10, 2018
Registered-Principal Register
Oct 10, 2018
Final Disposition Notice Created, To Be Sent To Ib
Oct 16, 2018
Generic Madrid Transaction Created
Oct 16, 2018
Generic Madrid Transaction Sent To Ib
Dec 21, 2018
Final Decision Transaction Processed By Ib
Apr 6, 2021
Correction From The Ib Examined, No Action Is Needed
Apr 9, 2021
New Representative At Ib Received
May 4, 2024
New Representative At Ib Received
Trademark Alertz updated from USPTO on 2030-01-24
